Drug Profile


Alternative Names: AZD-2281; KU-0059436; KU-59436; Lynparza

Latest Information Update: 20 May 2017

Price : $50

At a glance

  • Originator KuDOS Pharmaceuticals
  • Developer AstraZeneca; Cancer Research UK; Dana-Farber Cancer Institute; Eli Lilly; M. D. Anderson Cancer Center; Massachusetts General Hospital; Myriad Genetics; National Cancer Institute (USA); National Institute of Oncology; Netherlands Cancer Institute; NHS Greater Glasgow and Clyde; University of Oxford; University of Texas M. D. Anderson Cancer Center
  • Class Amides; Antineoplastics; Cyclopropanes; Fluorobenzenes; Phthalazines; Piperazines; Small molecules
  • Mechanism of Action Poly(ADP-ribose) polymerase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Ovarian cancer
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Ovarian cancer
  • Phase III Breast cancer; Pancreatic cancer; Prostate cancer
  • Phase II Solid tumours
  • Phase I/II Fallopian tube cancer; Glioblastoma; Head and neck cancer; Peritoneal cancer; Small cell lung cancer
  • Phase 0 Endometrial cancer
  • No development reported Colorectal cancer
  • Discontinued Gastric cancer

Most Recent Events

  • 25 May 2017 M.D. Anderson Cancer Center and AstraZeneca plans a phase I trial for Solid tumours (Combination therapy, Late-stage disease, Second-line therapy or greater) in USA (NCT03162627)
  • 04 Apr 2017 AstraZeneca and European Network of Gynaecological Oncology Trial Groups plan the phase IIIb OReO trial for Ovarian cancer (Second-line therapy or greater), including primary Peritoneal cancer and/or Fallopian tube cancer, in France (PO, Tablet) (NCT03106987)
  • 04 Apr 2017 AstraZeneca temporarily suspends an expanded access programme for Ovarian cancer (Monotherapy, Second-line therapy or greater) in Japan (NCT03063710)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top